Breaking News, Financial News

Financial Report: Dendreon

Revenues down 12% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Dendreon 4Q Revenues: $74.8 million (-12%) 4Q Loss: $88.7 million (loss of $38.7 million 4Q12) FY Revenues: $283.7 million (-13%) FY Loss: $296.8 million (loss of $393.6 million FY12) Comments: The company added 31 new accounts for PROVENGE in the quarter and implemented a new commercial model. The company will make PROVENGE available in Europe through Centers of Excellence using CMO PharmaCell, beginning with Germany and the UK. Royalty and other revenues were down to $7 million in the qua...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters